Elucidating the Space of Enzymatic Reaction: A Unified Benchmark and Pretrained Model
Organizations: Shanghai Jiao Tong University · Shanghai Artificial Intelligence Laboratory · The University of Sydney
Abstract
Existing reaction models primarily learn molecular transformations, whereas enzy- matic reactions depend jointly on molecular structure and catalytic function. We formulate this problem as learning an enzymatic reaction space linking reactants, products, and Enzyme Commission (EC) annotations. To characterize this space, we introduce VenusRX-Bench, a unified benchmark for forward reaction prediction, single-step retrosynthesis, and EC-number prediction. VenusRX-Bench integrates reactions from multiple biochemical databases with standardized curation, leakage- controlled splits, and consistent evaluation. Benchmarking representative chemical and enzymatic models reveals a clear chemical-to-enzymatic domain gap, driven by limited domain data, catalytic-context dependency, and the difficulty of modeling large biomolecular structures. To bridge this gap, we develop VenusRX, a unified T5-style sequence-to-sequence model for enzymatic reactions. VenusRX jointly learns forward prediction, ret- rosynthesis, and reaction reconstruction, with two-stage training on millions of template-expanded reactions followed by real biochemical reactions. In addition, optional EC conditioning incorporates catalytic context, while Molecule Library- Constrained Decoding improves the generation of complex biomolecules. Across benchmark tasks and challenging generalization splits, VenusRX achieves the best or competitive performance on most evaluated settings over representative chem- ical and enzymatic baselines. Moreover, EC information consistently improves reaction prediction, while learned reaction representations support accurate EC prediction, revealing a bidirectional relationship between reaction structure and catalytic function. Together, VenusRX-Bench and VenusRX provide a unified framework for elucidating and modeling enzymatic reaction space
Figures & tables
| Method | Reactant Split | Product Split | EC Split | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T1 | T3 | T5 | T10 | T1 | T3 | T5 | T10 | T1 | T3 | T5 | T10 | |
| Zero-shot | ||||||||||||
| R-SMILES ∗ ( Zhong et al., 2022 ) | 0.000 | 0.711 | 0.979 | 1.841 | 0.000 | 0.683 | 1.354 | 2.313 | 0.000 | 0.324 | 0.923 | 1.594 |
| Without EC Input | ||||||||||||
| R-SMILES | 70.562 | 82.048 | 85.543 | 88.618 | 30.849 | 44.631 | 50.000 | 55.849 | 15.568 | 28.104 | 34.899 | 44.643 |
| Graph2SMILES ( Tu & Coley, 2022 ) | 68.453 | 80.219 | 82.863 | 84.576 | 34.408 | 44.427 | 48.286 | 51.702 | 19.823 | 29.794 | 33.401 | 37.548 |
| Method | Reactant Split | Product Split | EC Split | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T1 | T3 | T5 | T10 | T1 | T3 | T5 | T10 | T1 | T3 | T5 | T10 | |
| Zero-shot | ||||||||||||
| SciReasoner ∗ (LLM) ( Wang et al., 2025 ) | 1.445 | 1.957 | 2.528 | 3.355 | 0.947 | 1.570 | 2.121 | 2.876 | 0.204 | 0.611 | 0.839 | 1.282 |
| R-SMILES ∗ | 0.000 | 0.687 | 2.004 | 2.656 | 0.000 | 1.007 | 2.073 | 2.601 | 0.000 | 0.228 | 0.527 | 0.899 |
| RSGPT ∗ ( Deng et al., 2025a ) | 0.058 | 0.082 | 0.128 | 0.373 | 0.000 | 0.048 | 0.132 | 0.204 | 0.024 | 0.048 | 0.192 | 0.527 |
| Without EC Input | ||||||||||||
| Method | Reactant Split | Product Split | ||||||
|---|---|---|---|---|---|---|---|---|
| EC1 | EC2 | EC3 | EC4 | EC1 | EC2 | EC3 | EC4 | |
| Zero-Shot | ||||||||
| crxnfp ( Zhang et al., 2025 ) | ||||||||
| DRFP ( Probst et al., 2022b ) | ||||||||
| rxnfp ( Schwaller et al., 2021b ) | ||||||||
| VenusRX ∗ | ||||||||
| Variant | Training Objectives | Stage-1 | Stage-2 | Forward (with EC) | Retrosynthesis (with EC) | EC Prediction | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fwd. | Retro. | MLM | Top-1 | Top-5 | Top-10 | Top-1 | Top-5 | Top-10 | EC1 | EC2 | EC3 | EC4 | |||
| Full | 75.221 | 89.725 | 92.474 | 17.230 | 29.345 | 34.425 | 94.76 | 87.76 | 82.81 | 51.17 | |||||
| w/o MLM | – | 75.175 | 89.119 | 92.020 | 17.160 | 27.691 | 32.013 | 92.53 | 85.14 | 80.31 | 49.54 | ||||
| w/o Stage-1 | – | 47.192 | 71.086 | 77.178 | 7.130 | 17.882 | 22.682 | 89.86 | 80.78 | 75.49 | 45.17 | ||||
| w/o Stage-2 | – | 35.450 | 54.578 | 60.881 | 6.454 | 14.003 | 17.999 | 94.41 | 87.01 | 82.03 | 49.38 | ||||
Appendix figures & tables11 assets
Supplementary material from the paper’s appendix.
Appendix
| Split | Train | Validation | Test |
|---|---|---|---|
| Reactant Split | 66,672 | 8,183 | 8,584 |
| Product Split | 66,751 | 8,344 | 8,344 |
| EC Split | 66,751 | 8,344 | 8,344 |
| Model | Enc./Dec. | Heads | Parameters | |||
|---|---|---|---|---|---|---|
| Micro | 4/4 | 256 | 1,024 | 4 | 64 | 7,554,816 |
| Compact | 6/6 | 320 | 1,280 | 5 | 64 | 17,495,296 |
| Tiny | 6/6 | 384 | 1,536 | 6 | 64 | 25,147,648 |
| Medium | 6/6 | 768 | 3,072 | 12 | 64 | 100,135,168 |
| Task | Source | Target |
|---|---|---|
| Forward | <forward> >><mask_product><ec_number> | |
| Retro | <retro> <ec_number> | |
| Span | <mlm> >> ) <ec_number> | Masked spans |
| Split | Retained records | 20-view records | Zero-view records | Stored views |
|---|---|---|---|---|
| Reaction | 4,044,455 | 3,660,831 | 383,624 | 73,216,620 |
| EC | 3,853,604 | 3,471,243 | 382,361 | 69,424,860 |
| Product | 4,047,718 | 3,665,111 | 382,607 | 73,302,220 |
| Setting | Stage one | Stage two |
|---|---|---|
| Initialization | Random | Stage-one best weights |
| Optimizer | AdamW | AdamW |
| Adam betas | ||
| Weight decay | 0 | 0 |
| Peak learning rate | ||
| Warmup steps | 1,000 | 1,000 |
| Run | Stage one | Stage two |
|---|---|---|
| Micro, reaction | 544,000 / 630,080 | 86,000 / 91,136 |
| Compact, reaction | 400,000 / 488,312 | 72,000 / 77,074 |
| Tiny, reaction | 288,000 / 378,048 | 75,000 / 80,100 |
| Medium, reaction | 240,000 / 330,792 | 38,000 / 43,076 |
| Tiny, EC | 336,000 / 420,196 | 72,000 / 77,000 |
| Tiny, product | 176,000 / 268,022 | 67,000 / 72,100 |
| Task | EC Input | Reactant Split | Product Split | EC Split | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T1 | T3 | T5 | T10 | T1 | T3 | T5 | T10 | T1 | T3 | T5 | T10 | ||
| Forward | Without EC | 73.066 | 84.611 | 88.048 | 90.739 | 50.959 | 66.275 | 71.393 | 77.085 | 31.100 | 45.170 | 53.236 | 59.947 |
| With EC | 75.221 | 86.778 | 89.725 | 92.474 | 55.825 | 69.463 | 74.041 | 78.811 | 34.564 | 50.240 | 56.340 | 64.058 | |
| Retrosynthesis | Without EC | 8.446 | 17.183 | 23.777 | 30.603 | 20.554 | 30.058 | 34.923 | 39.945 | 4.878 | 8.737 | 10.487 | 14.274 |
| With EC | 17.230 | 26.398 | 29.345 | 34.425 | 28.847 | 34.696 | 38.267 | 40.568 | 18.360 | 24.605 | 27.481 | 30.872 | |
| Method | Reactant Split | Product Split | EC Split | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C@1 | C@3 | C@5 | C@10 | C@1 | C@3 | C@5 | C@10 | C@1 | C@3 | C@5 | C@10 | |
| Zero-shot | ||||||||||||
| SciReasoner ∗ (LLM) | 31.163 | 45.853 | 52.260 | 61.125 | 20.206 | 30.489 | 36.266 | 44.487 | 17.953 | 29.782 | 36.937 | 46.045 |
| RSGPT ∗ | 14.247 | 25.524 | 29.555 | 34.098 | 8.881 | 14.861 | 16.982 | 19.427 | 8.198 | 17.797 | 21.201 | 24.904 |
| R-SMILES ∗ | 3.856 | 9.879 | 13.898 | 19.385 | 2.721 | 6.807 | 10.139 | 14.849 | 4.830 | 8.401 | 12.548 | 19.691 |
| Without EC Input | ||||||||||||
| Method | Reactant Split | Product Split | EC Split | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A@1 | A@3 | A@5 | A@10 | A@1 | A@3 | A@5 | A@10 | A@1 | A@3 | A@5 | A@10 | |
| Zero-shot | ||||||||||||
| SciReasoner ∗ (LLM) | 31.163 | 24.282 | 20.503 | 17.672 | 20.206 | 14.533 | 12.081 | 9.340 | 17.953 | 13.774 | 12.157 | 9.939 |
| RSGPT ∗ | 14.247 | 12.950 | 10.848 | 7.780 | 8.881 | 6.935 | 5.297 | 3.496 | 8.198 | 7.674 | 6.764 | 4.715 |
| R-SMILES ∗ | 3.856 | 4.042 | 4.268 | 3.929 | 2.721 | 2.621 | 2.812 | 2.641 | 4.830 | 3.356 | 3.490 | 3.476 |
| Without EC Input | ||||||||||||
| Method | Reactant Split | Product Split | ||||||
|---|---|---|---|---|---|---|---|---|
| EC1 | EC2 | EC3 | EC4 | EC1 | EC2 | EC3 | EC4 | |
| Zero-Shot | ||||||||
| crxnfp ( Zhang et al., 2025 ) | ||||||||
| DRFP ( Probst et al., 2022b ) | ||||||||
| rxnfp ( Schwaller et al., 2021b ) | ||||||||
| VenusRX ∗ | ||||||||
| Split | EC | Unconstrained | MLCD |
|---|---|---|---|
| Reactant | ✓ | 2.277 | 0.000 |
| – | 1.599 | 0.000 | |
| Product | ✓ | 3.641 | 0.000 |
| – | 2.756 | 0.000 | |
| EC | ✓ | 3.086 | 0.000 |
| – | 2.210 | 0.000 |